Creso Pharma Limited provided the update to shareholders on its growing revenue profile and record start to fiscal year 2021. The Company wishes to advise that it has secured a new purchase order for its leading range of animal health products anibidiol®, from existing commercial partner, Virbac Switzerland. The PO is a repeat order, is non-cancellable and is valued at CHF 171,000 (AUD 247,8261). Creso Pharma expects to complete delivery of the PO in April 2021. This PO adds to a number of orders that Creso Pharma has secured in the recent weeks including three respective POs for anibidiol® valued at CHF 277,000 (AUD 401,4491) from current commercial partners. The Company expects to fulfil these orders during the current quarter, with the sale to be banked shortly after.